Relmada Therapeutics(RLMD) - 2023 Q4 - Annual Report
Relmada Therapeutics(RLMD)2024-03-20 04:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number: 000-55347 Relmada Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 45-5401931 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identi ...